RecruitingNot ApplicableNCT06037941

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

20 participants

Start Date

Sep 8, 2023

Study Type

INTERVENTIONAL

Conditions

Malignant Pleural Mesothelioma

Summary

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.

Eligibility

Min Age: 30 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether an "electronic nose" device — a sensor that detects chemical patterns in a person's breath — can track how well treatment is working in patients with malignant pleural mesothelioma, a rare cancer affecting the lining of the lungs. **You may be eligible if...** - You are 30–85 years old - You have recently been diagnosed with malignant pleural mesothelioma - You are scheduled for surgical removal of the tumor **You may NOT be eligible if...** - You are younger than 30 or older than 85 - You have a history of other chest cancers or cancers known to spread to the lungs (such as breast, stomach, colon, or pancreatic cancer) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTE-Nose testing

At baseline (before any treatment is administered) approximately when the patient is scheduled for a CT of the Chest and/or PET/CT after initiation of any treatment, as medically permissible and at the PI's discretion. A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.

DIAGNOSTIC_TESTResearch blood

Research blood tests will be obtained at baseline and the first three standard of care follow up visits, scheduled by their treating physician along with a CT of the Chest and/or PET/CT1 to determine whether serum biomarkers of MPM.